Couldn't find what you looking for?

TRY OUR SEARCH!

Hereditary breast cancers account for up to fifth of all cases of this disease. Modern methods of genetic testing allow to identify the individuals at risk and advice on the best preventative strategy.

Although most cancers are sporadic, some run in the same family from generation to generation. Some types of breast cancer have strongly been associated with a family history. With our constantly improving knowledge of human genetics, we now have a much better understanding of reasons behind this inherited pattern of breast cancers. Moreover, we can calculate the risk and take helpful preventive measures to avoid the disease.

The hereditary aspect of breast cancer

Scientists estimate that between 10 and 20 percent of breast cancer patients have a relative (first or second order) who has already suffered from the same disease.
 

This is a clear indication that some common genes are at play here. Some of the most well-known and best studied heritable genes linked to the development of breast cancer are the mutant forms of the BRCA genes (BRCA1 and BRCA2). They are often referred to as high susceptibility genes. The mutations in these genes are inherited in an autosomal dominant pattern. This means that the presence of a single mutant gene copy is sufficient to cause the diseased condition.

The effect of BRCA mutations can be clearly seen in a small northern European nation of Iceland. This country has the largest rate of breast cancer in the entire world. Iceland's breast cancer rate is almost twice as high as the world’s average. Researchers believe that this is a consequence of so-called “founder’s effect”. The whole nation was established by just few families who migrated to the island from Norway. Apparently, one of the women brought to the island was a carrier of the defective BRCA gene, and she then passed that gene on to all her descendants, up to this very day.

More recent scientific studies show that many other genes can influence the risk of breast cancer in addition to the notorious BRCA mutations. For instance, a specific mutation in the CHEK2 gene (a cell cycle check point kinase) increases the chance of breast cancer risk among women twofold while increasing the risk of breast cancer in men by a factor of 10. Mutations in the gene PALB2 have been linked to increased breast cancer risks and its pattern of mutation is quite similar to those of BRCA2. Rare mutations in BRIP1, ATM, NBS1 and Rad51 also contribute to nearly 2-fold increment in breast cancer chances.

Now researchers are discussing the ‘multiple rare alleles - common disease’ model that involves the formation of a complex of eight genes that might regulate breast cancer. However, the origin of the half of all hereditary breast cancer cases still remains unknown. Involvement of many more genes and their mutants are yet to be unraveled to understand the hereditary aspect of breast cancer. Genome wide association studies (GWAS) are increasingly used to identify common genetic variants that might be involved in the development of this disease.

Individual risk of hereditary breast cancer can be predicted and calculated

A family history of breast cancer does provide some clue with regarding to the individual chances of getting the disease. But the proper assessment of your personal cancer risk can be done only with the use of modern genetic testing. Fortunately, these days it is possible to have this done, and the risk calculations are quite precise.

Genetics, however, is not the only factor that has to be taken into consideration when you assess your risk of breast cancer. An interesting study published in Lancet Oncology by a group of scientists from Cancer Research UK has linked breast cancer with the levels of sex hormones in women under the age of 50.

The increase in the risk of breast cancer was found to be directly proportional to the higher level of sex hormones like oestradiol and oestrone.

This is an important finding considering the fact that 1 in 5 women under the age of 50 are diagnosed with breast cancer.

What can be done if your risk of breast cancer is high: existing preventive approaches

Angelina Jolie’s revelation that she had opted to undergo a double mastectomy (the surgical removal of both breasts) has caught attention of the press and the public alike. In the Hollywood star’s case, genetic testing revealed that her chances of getting the disease were a shocking 87%. With such huge odds against her, the actress decided to proceed with the radical preventative strategy of having both her breasts removed.

It is quite rare for the genetic risks of breast cancer to be so high. What should be done in those cases when risk is smaller but still significant? Careful monitoring of patients at risk is good for early detection of disease, but do we have any strategies that would reduce the chances of getting cancer?

At present time, preventative drug therapy is the most prevalent strategy for such cases. Preventative drugs are actually the same that are used for treating breast cancer patients. These are so-called selective estrogen receptor modulators (SERM), usually tamoxifen or raloxifene. A 5 years prophylactic course of these drugs reportedly causes a 50% decrease in the risk of developing cancer.

However, the use of these drugs does face strong opposition. The drugs are known to cause severe side effects such as blood clotting, stroke and endometrial cancer. As a result, statistically a patient might reduce her risk of getting breast cancer through this therapy but increases the chances of dying from other causes.

Also, not all patients seem to respond to this therapy equally well. It is therefore important to identify and treat only those people who are more likely to benefit from the treatment. Recently published findings by Ingle and co-authors established a relationship between previously unknown variants of genes ZNF423 and CTSO and the potential of breast cancer patients to respond to SERM. The presence of these two genetic markers significantly enhanced the response of the patients to the drugs. Specific testing for these mutations can significantly improve the predictability of preventative treatment.

Genetic testing for breast cancer: A work in progress

Personalized genetic testing and screening aimed to assess an individual's chances of developing breast cancer is the order of the day if we are serious about the prevention of this disease. With the help of modern day technologies, genetic testing for the breast cancer susceptible genes is a relatively easy option.

The testing can clearly identify those at higher risk, as well as save many patients from unnecessary treatment from which they won’t benefit.

There is also a need to better understand the underlying mechanisms of breast cancer and its genetic component.  This can lead to the finding of more precise and individualized preventative treatment approaches.

Read full article

  • Walsh T, King MC. (Feb 2007) Ten genes for inherited breast cancer, 11: 103-105
  • Husing A, Canzian F et al. (Sep 2012) Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status, J. Med. Genet. 49: 601-608
  • Ingle JN, Liu M, Wickerham DL et al. (June 2013) Selective estrogen receptor modulators and pharmacogenomics variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discovery, 3: 812-825
  • Ingle JN. (Jun 2013) Pharmacogenomics of endocrine therapy in breast cancer, J Hum Genet. 58:306-312.
  • Photo courtesy of rachel a. k. by Flickr : www.flickr.com/photos/kimonomania/2913549908/
  • Photo courtesy of TipsTimes by Flickr : www.flickr.com/photos/tipstimes/7483072476/

Your thoughts on this

User avatar Guest
Captcha